A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!